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SI.]MMARY AND CONCLUSIONS.
Dopamine is generally considered as a valuable drug in clinical medicine. The
expression "renal dose" of dopamine is often used and known to most physicians. This
illustrates not only that they are familiaÍ with the idea of a specific dose range to obtain
the desired effects but also the value attributed to these renal effects of the drug.
Infusion of dopamine results in an increase in renal blood flow, glomerular filtration
and sodium excretion. This is the result, of stimulation of specific dopamine receptors.
At higher dopamine infusion rates, renal blood flow and glomerular filtration fall again
which is usually ascribed to stimulation of adrenoceptors, resulting in renal vaso-
constriction. The link between the effects of dopamine and stimulation of specific
receptors has been based on pharmacological studies using dopamine and adrenergic
receptor agonists and antagonists.
The facts that dopamine is present in the kidney and in even much larger amounts in
urine, that specific dopamine receptors exist within the kidney, and that stimulation of
Íhese receptors elicits such marked renal effects, makes it attractive to suppose an
important physiological role for this third naturally occurring catecholamine in the
kidney.
This thesis describes the renal effects of some dopamine and alpha-adrenergic
receptor antagonists before and during infusion of dopamine in various doses in normal
man and in patiens with renal disease. An attempt is made to draw some conclusions
on the physiological and possibly pathophysiological role of endogenous dopamine.
Chapter I provides an extensive review of the renal effects of dopamine. In the
historical section the importance of adequate dose-finding studies is highlighted. After
a description of the various receptors which may be stimulated by dopamine, the renal
effects of exogenous and of endogenous dopamine are discussed sepaÍately. Several
mechanisms may be responsible for dopamine-induced natriuresis. The renal vaso-
dilation per se has often been considered as the main faclor; however, recent evidence
supports the assumption ftat direct tubular effects of dopamine are at least com-
plementary. The inhibition of aldosterone release by dopamine may also contribute to
the natriuretic effect of dopamine. A pathophysiological role of defective dopamine
generation in essential hypertension and some oedematous disorders like congestive
heart failure has been suggested but the available evidence does not allow firm
conclusions in this respect. This does not exclude a possibly valuable role in the
treatÍnent of such diseases for selective and orally active dopamine agonists which have
recently become available for clinical use.
Chapter 2 states the purpose of Íre studies which were performed in normal
volunteers and in patients with renal disease and moderately impaired renal function. A
general description of the study population, the study protocols and the methods is
given.
Chapter 3 describes the renal effects of dopamine dose-response curves in normal
volunteers and patients with renal disease. In eailier studies of Beukhof et al in patients
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with IgA-glomerulopathy, and of ter Wee et al in a larger group of patients with various
renal diseases, an impaired response of ERPF and GFR to infusion of a hxed dose of
1.5-2.0 pg/kg,/min dopamine compared to normal volunteers was found. Below a base-
line GFR of 73 mUminll;|3 mz dopamine did not change ERPF or GFR; above this
level the dopamine-induced rise in ERPF and GFR was larger with increasing base-line
GFR. Even when the base-line GFR of a patient with renal disease was within the
normal range his response to the fixed dose of dopamine was impaired compared to a
healttry control subject. It was concluded that in patients with renal disease, nephron
loss could be compensated for by a progressive utilization of the so called reserve
filtration capacity. The possibility was proposed that an increase in endogenous renal
dopamine was involved in this recruitment of reserve filtration capacity: renal
vasodilation resulting from stimulated renal dopamine generation compensates for a
fall in renal blood flow after nephron loss in a patient with renal disease. If such a
hypothesis is true, ttre validity of a fixed-dose dopamine infusion for testing reserve
filtration capacity can even be questioned: an impaired renal haemodynamic response
cannot be assumed to represent only a fall in recruitable renal vasodilatory potential but
may also reflect the competition of exogenous dopamine and stimulated endogenous
dopamine for binding to dopamine receptors which induce renal vasodilation.
We decided to test the hypothesis of enhanced renal dopamine generation in patiens
with renal disease both by studying the effects of dopamine antagonists and by
performing dose-response studies with exogenous dopamine. If renal disease would be
associated with an increased renal dopamine generation, an enhanced sensitivity to
dopamine antagonists, revealed by a renal vasoconstrictory response and possibly a fall
in sodium excretion, should be found. A flauened dose-response curve, not only
absolutely but also percentually, for exogenous dopamine would form another, albeit
less persuasive argument for enhanced renal dopamine generation.
The results in chapter 3 show that for the renal haemodynamic parameters in
patients with renal disease compared to healthy volunteers, an impaired percentual
response was indeed found. In the normal volunteers a marked dose-dependent. renal
vasodilatory response was established which was already evident at a dose of 0.25 ltgl
kg/min, and reached its maximum at a dose of 4 pg/kg/min. The increase in GFR was
modest. The reduction in the renal vasodilatory response in the patients with renal
disease was found for the complete dose-range of dopamine. However, the natriuretic
response to dopamine did not differ beween the patients and the healthy volunteers.
This casts some doubt on the hypothesis of an enhanced renal dopamine generation,
although a local vascular increase in dopamine generation cannot be excluded. The fact
that patiens with renal disease had an impaired renal vasodilatory but a conserved
natriuretic response to dopamine, formed our first argument for the assumption that the
dopamine-induced natriuresis does not depend on renal vasodilation. As discussed
above, direct tubular effects or an aldosterone-inhibiting action of dopamine might be
other factors involved in the increase in sodium excretion. Additional arguments for a
direct tubular action were supplied by the observed changes in the excretions of
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Further arguments to refute the hypothesis that enhanced endogenous dopamine
generation in patients with renal disease is responsible for their impaired renal vaso-
dilatory response to exogenous dopamine were provided by the study described in
chapter 4. Vy'e xamined the effect of the dopamine antagonist metoclopramide on base-
line values and dopamine dose-response curves for renal haemodynamics and sodium
excretion in healthy volunteers and in patients with renal disease.
Metoclopramide shifted the dopamine dose-response curve for renal vasodilation in
the healthy volunteers and may therefore be assumed to act as a dopamine antagonist in
tle human kidney. Neither in the healthy volunteers nor in the patients with renal
disease was any effect on base-line values of ERPF or FF found, thereby undermining
the assumption that the impaired renal vasodilatory Íesponse in Íre patients with renal
disease is due to enhanced endogenous dopamine generation. However, metoclo-
pramide induced a fall in sodium excretion and a shift of the dopamine dose-response
curve for natriuresis. This might represent the contribution of endogenous dopamine to
sodium excretion on tle one hand and is a second argument. for a natriuretic action of
dopamine which is independent of its renal vasodilatory effect on the other hand. One
might presume that, while the renal effecs of exogenous dopamine comprise both renal
vasodilation and natriuresis, endogenous dopamine has no influence whatsoever on
renal vessels and its only role is in modulating sodium excretion. However the
demonstration of dopamine receptors in several renal vessel types and the observation
that very high doses of metnclopramide may decrease renal plasma flow argue against
such an assumption. The observed changes in the fractional excretions of y-
glutamyltransferase and p-2-microglobulin again support a direct (proximal) tubular
effect of dopamine. The observed fall in aldosterone concentration during dopamine
infusion and its rise during metoclopramide draw attention to the contributory role of
aldosterone in the natriuretic effect of dopamine.
In chapter 5 the effects of another dopamine antagonist, sulpiride, have been
examined. For metoclopramide other human snrdies had suggested dopamine
antagonist activity at the renal level; for sulpiride comparable vidence from studies in
man was scant despite the fact that in animal studies this drug is a very potent
antagonist of dopamine-induced renal vasodilation. Therefore, and also because sul-
piride in contrast o many other potent or selective dopamine antagonists is clinically
available, we started a study of is effect on dopamine-induced renal vasodilation in
healthy volunteers. To our surprise no effect whatsoever on the dopamine dose-
response curves for ERPF or FF could be found. A fall in sodium excretion at base-line
and its impaired response to dopamine infusion was assumed by us lo represent a
dopamine antagonist action of sulpiride on the natriuretic effects of endogenous and
exogenous dopamine, respectively, which made it less likely that the dose of sulpiride
had been too low to detect antagonist activity on dopamine-induced renal vasodilation.
In the animal studies investigating the effects of sulpiride on dopamine-induced renal
vasodilation, pretreatment with alpha-adrenergic antagonists had been used to block the
alpha-adrenergic effects of dopamine. As sulpiride is known to possess ome alpha-
antagonist activity, we discussed the possibility that this might have obscured the
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dopamine antagonist activity in our studies. We decided to repeat our sulpiridc studies
after pretreatment with alpha-blockers. Pending the results of alpha-blocker ex-
periments, we discontinued the sulpiride studies in patients with renal disease of whom
three had been investigated sofar. The results of these patients are also mentioned in
chapter 5. Meanwhile the contrast between ttre antinatriuretic effect of sulpiride and the
lack of effect on dopamine-induced renal vasodilation formed anotler argumcnt for a
dissociation between dopamine-induced renal vasodilation and natriuresis.
Chapter 6 is devoted to the relation of alpha-adrenergic and dopaminergic renal
effecs. In the first two parts of this chapter dopamine dose-response curves without
and with sulpiride are described after pretreatment with the selective alpha-l-blocker
prazosin and the aselective alpha-adrenoceptor antagonist phentolamine, respectively.
We conclude that sulpidde does not show any activity as an antagonist of dopamine-
induced renal vasodilation in man during pretreatment with either prazosin or
phentolamine. The earlier observed fall in sodium excretion is confirmed and again
supports a role for endogenous dopamine in maintaining sodium excretion. We cannot
explain why this potent antagonist of dopamine-induced renal vasodilation in various
animal studies fails to show any such effect in our human experiments. During both
forms of prefeatment with an alpha-blocker dopamine lost its natriuretic effect.
Therefore we performed a separate study comparing dopamine dose-response curves
with and without prazosin pretreatment in which prazosin was found to impair not only
the natriuretic but also the renal vasodilatory action of dopamine, although base-line
values were not altered by prazosin. A comparable study in patients with renal disease
gave somewhat different results: while base-line sodium excretion fell and the patients
also exhibited an abolished natriuretic response to dopamine during prazosin
pretreatment, base-line values of ERPF, GFR or FF nor their renal vasodilatory
response to dopamine were affected by prazosin. Several possibilities to explain this
unexpected reduction in ttre natriuretic response to dopamine are discussed. One of the
proposed theories suggests that alpha-blockade results in enhanced endogenous renal
dopamine generation. Although this theory covers most of the observations in this
study, no other clinical or experimental studies or data on dopamine levels are available
to suppoÍ such a theory which, therefore, remains speculative. Another theory involves
the selective effects of the DA1 dopamine and the alpha-l adrenoceptor on phospho-
lipase-C and its relation to sodium excretion. Stimulation of alpha-1 adÍenoceptors is a
prerequisite for phospholipase activation and might explain why alpha-blockade in our
studies abolished a phospholipase-C-mediated nariuretic response !o dopamine. In this
theory we also propose the blunted response of the ERPF to dopamine infusion during
prazosin pretreatment to be a consequence ( and not a cause) of the abolished natriu-
retic response. In fact, a synergistic effect of alpha-l adrenoceptor and DA1 dopamine
receptor stimulation on phospholipase-C-mediated sodium excretion might explain the
disproportionate rise in sodium excretion during infusion of dopamine in doses at
which ERPF starts to fall due to the vasoconstrictory effect of alpha-adrenergic
stimulation. The present studies also examined for the first. time the acute (within one
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Finally, in chapter 7 we investigated plasma and urine free dopamine levels under
the study conditions which had been used in the previous chapters. No change in these
levels could be detected under our base-line study conditions which included moderate
hydration in volunteers which were in a supine position ( except for voiding), and
repeated venapunctuÍe. No evidence for a possible circadian rhythm during our study
period was found. Infusion of dopamine at doses of 0.25 and 0.5 pgltg/min resulted in
huge increases in plasma dopamine levels while urine dopamine rose to levels slightly
above the physiological range. At higher infusion rates which were associated with
observable renal effects in our earlier studies, a sharp increase in urine dopamine was
observed while that of plasma dopamine became less ou8poken. We concluded that the
observation made under physiological circumstances ttrat there is a far better
correlation between the assumed renal effects of endogenous dopamine and urine
dopamine than plasma dopamine, is also valid for the renal effects of exogenous
dopamine. Phentolamine but not prazosin administration was associated with a small
rise in plasma dopamine. Urine dopamine was changed by neither of them, a finding
which undermines the theory of an increase in endogenous renal dopamine during
alpha-blockade which had been proposed in chapter 6. When our preliminary data on
dopamine levels in patients with renal disease ÍrÍe confirmed, including the low urine
dopamine excretion (even when corected for a normal GFR), this will form another
objection to our earlier formulated hypothesis of an enhanced endogenous renal
dopamine generation in patients with renal disease.
In conclusion our pharmacological studies have confirmed an impaired renal
vasodilatory response in patients with renal disease. However, their natriuretic response
to dopamine is conserved. No supportive evidence was found for the assumption that
the impaired renal vasodilatory response to dopamine in Íre patients with renal disease
is due to enhanced endogenous dopamine generation. Both in normal volunteers and
patients with renal disease, endogenous dopamine seems to have a role in sodium
excretion. The dopamine-induced natriuresis does not depend on renal vasodilation but
is probably due to direct proximal tubular effecs although inhibition of aldosterone
secretion may contribute to the natriuretic effect of dopamine. Mctoclopramide but not
sulpiride was shown to act as an antagonist of dopamine-induced renal vasodilation;
both drugs antagonized dopamine-induced natriuresis. Alpha-blockade, both selective
alpha-1-adrenergic using prazosin and aselective using phentolamine, abolished
dopamine-induced natriuresis by an as yet unknown mechanism.
Studies using selective agonists and antagonists for DA1 and DA, dopamine
receptors may allow a better definition of the contribution of various receplors to the
renal effects of endogenous and exogenous dopamine.
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